The benefits of achieving stable disease in advanced lung cancer

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The cytostatic, molecular-targeted therapies becoming available for lung cancer and other human solid tumors are more likely to result in stable disease than to produce tumor regression. In the setting of advanced lung cancer, stable disease provides significant benefit to the patient. However, in the context of clinical trials, stable disease is vaguely defined, difficult to measure, and may represent a heterogeneous patient population. The inclusion of alternative trial end points such as symptom improvement and biologic activity may help to identify patients who have achieved clinically relevant stable disease. The epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib (Iressa) has been shown to produce partial responses and stable disease in patients with advanced lung cancer who have previously received treatment with standard chemotherapies. In the monotherapy trials of gefitinib, stable disease was correlated with improvements in disease- related symptoms and quality of life-the most meaningful end points for the patient with advanced lung cancer. Thus, with the introduction of new molecular-targeted agents, stable disease with clinical benefit should become an important goal of anticancer therapy.

Original languageEnglish (US)
Pages (from-to)957-963
Number of pages7
JournalOncology
Volume17
Issue number7
StatePublished - Jul 2003
Externally publishedYes

Fingerprint

Lung Neoplasms
Molecular Targeted Therapy
Cytostatic Agents
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Neoplasms
Quality of Life
Clinical Trials
Drug Therapy
Therapeutics
Population
gefitinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The benefits of achieving stable disease in advanced lung cancer. / Kelly, Karen.

In: Oncology, Vol. 17, No. 7, 07.2003, p. 957-963.

Research output: Contribution to journalArticle

@article{19bd332c5e764fe9a83d66153c5d6188,
title = "The benefits of achieving stable disease in advanced lung cancer",
abstract = "The cytostatic, molecular-targeted therapies becoming available for lung cancer and other human solid tumors are more likely to result in stable disease than to produce tumor regression. In the setting of advanced lung cancer, stable disease provides significant benefit to the patient. However, in the context of clinical trials, stable disease is vaguely defined, difficult to measure, and may represent a heterogeneous patient population. The inclusion of alternative trial end points such as symptom improvement and biologic activity may help to identify patients who have achieved clinically relevant stable disease. The epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib (Iressa) has been shown to produce partial responses and stable disease in patients with advanced lung cancer who have previously received treatment with standard chemotherapies. In the monotherapy trials of gefitinib, stable disease was correlated with improvements in disease- related symptoms and quality of life-the most meaningful end points for the patient with advanced lung cancer. Thus, with the introduction of new molecular-targeted agents, stable disease with clinical benefit should become an important goal of anticancer therapy.",
author = "Karen Kelly",
year = "2003",
month = "7",
language = "English (US)",
volume = "17",
pages = "957--963",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "7",

}

TY - JOUR

T1 - The benefits of achieving stable disease in advanced lung cancer

AU - Kelly, Karen

PY - 2003/7

Y1 - 2003/7

N2 - The cytostatic, molecular-targeted therapies becoming available for lung cancer and other human solid tumors are more likely to result in stable disease than to produce tumor regression. In the setting of advanced lung cancer, stable disease provides significant benefit to the patient. However, in the context of clinical trials, stable disease is vaguely defined, difficult to measure, and may represent a heterogeneous patient population. The inclusion of alternative trial end points such as symptom improvement and biologic activity may help to identify patients who have achieved clinically relevant stable disease. The epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib (Iressa) has been shown to produce partial responses and stable disease in patients with advanced lung cancer who have previously received treatment with standard chemotherapies. In the monotherapy trials of gefitinib, stable disease was correlated with improvements in disease- related symptoms and quality of life-the most meaningful end points for the patient with advanced lung cancer. Thus, with the introduction of new molecular-targeted agents, stable disease with clinical benefit should become an important goal of anticancer therapy.

AB - The cytostatic, molecular-targeted therapies becoming available for lung cancer and other human solid tumors are more likely to result in stable disease than to produce tumor regression. In the setting of advanced lung cancer, stable disease provides significant benefit to the patient. However, in the context of clinical trials, stable disease is vaguely defined, difficult to measure, and may represent a heterogeneous patient population. The inclusion of alternative trial end points such as symptom improvement and biologic activity may help to identify patients who have achieved clinically relevant stable disease. The epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib (Iressa) has been shown to produce partial responses and stable disease in patients with advanced lung cancer who have previously received treatment with standard chemotherapies. In the monotherapy trials of gefitinib, stable disease was correlated with improvements in disease- related symptoms and quality of life-the most meaningful end points for the patient with advanced lung cancer. Thus, with the introduction of new molecular-targeted agents, stable disease with clinical benefit should become an important goal of anticancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=1842513804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842513804&partnerID=8YFLogxK

M3 - Article

C2 - 12886865

AN - SCOPUS:1842513804

VL - 17

SP - 957

EP - 963

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 7

ER -